Literature DB >> 26273065

Feasibility Study of Canine Epidermal Neural Crest Stem Cell Transplantation in the Spinal Cords of Dogs.

Barbara G McMahill1, Mathieu Spriet1, Sílvia Sisó1, Michael D Manzer1, Gaela Mitchell1, Jeannine McGee1, Tanya C Garcia1, Dori L Borjesson1, Maya Sieber-Blum1, Jan A Nolta1, Beverly K Sturges2.   

Abstract

UNLABELLED: This pilot feasibility study aimed to determine the outcome of canine epidermal neural crest stem cell (cEPI-NCSC) grafts in the normal spinal cords of healthy bred-for-research dogs. This included developing novel protocols for (a) the ex vivo expansion of cEPI-NCSCs, (b) the delivery of cEPI-NCSCs into the spinal cord, and (c) the labeling of the cells and subsequent tracing of the graft in the live animal by magnetic resonance imaging. A total of four million cEPI-NCSCs were injected into the spinal cord divided in two locations. Differences in locomotion at baseline and post-treatment were evaluated by gait analysis and compared with neurological outcome and behavioral exams. Histopathological analyses of the spinal cords and cEPI-NCSC grafts were performed at 3 weeks post-transplantation. Neurological and gait parameters were minimally affected by the stem cell injection. cEPI-NCSCs survived in the canine spinal cord for the entire period of investigation and did not migrate or proliferate. Subsets of cEPI-NCSCs expressed the neural crest stem cell marker Sox10. There was no detectable expression of markers for glial cells or neurons. The tissue reaction to the cell graft was predominantly vascular in addition to a degree of reactive astrogliosis and microglial activation. In the present study, we demonstrated that cEPI-NCSC grafts survive in the spinal cords of healthy dogs without major adverse effects. They persist locally in the normal spinal cord, may promote angiogenesis and tissue remodeling, and elicit a tissue response that may be beneficial in patients with spinal cord injury. SIGNIFICANCE: It has been established that mouse and human epidermal neural crest stem cells are somatic multipotent stem cells with proved innovative potential in a mouse model of spinal cord injury (SCI) offering promise of a valid treatment for SCI. Traumatic SCI is a common neurological problem in dogs with marked similarities, clinically and pathologically, to the syndrome in people. For this reason, dogs provide a readily accessible, clinically realistic, spontaneous model for evaluation of epidermal neural crest stem cells therapeutic intervention. The results of this study are expected to give the baseline data for a future clinical trial in dogs with traumatic SCI. ©AlphaMed Press.

Entities:  

Keywords:  Adult stem cells; Canine epidermal neural crest stem cell; Canine epidermal neural crest stem cells; Dog model; Epidermal neural crest stem cell; Spinal cord injury

Mesh:

Year:  2015        PMID: 26273065      PMCID: PMC4572898          DOI: 10.5966/sctm.2015-0018

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  43 in total

Review 1.  Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles.

Authors:  Morteza Mahmoudi; Heinrich Hofmann; Barbara Rothen-Rutishauser; Alke Petri-Fink
Journal:  Chem Rev       Date:  2011-12-30       Impact factor: 60.622

Review 2.  Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine.

Authors:  Morteza Mahmoudi; Hossein Hosseinkhani; Mohsen Hosseinkhani; Sebastien Boutry; Abdolreza Simchi; W Shane Journeay; Karthikeyan Subramani; Sophie Laurent
Journal:  Chem Rev       Date:  2010-11-15       Impact factor: 60.622

Review 3.  Designing clinical trials in canine spinal cord injury as a model to translate successful laboratory interventions into clinical practice.

Authors:  N D Jeffery; L Hamilton; N Granger
Journal:  Vet Rec       Date:  2011-01-29       Impact factor: 2.695

4.  Executive board actions range from strategic plan to stem cells.

Authors: 
Journal:  Am J Vet Res       Date:  2011-08       Impact factor: 1.156

5.  Effects of trial repetition, limb side, intraday and inter-week variation on vertical and craniocaudal ground reaction forces in clinically normal Labrador Retrievers.

Authors:  B Nordquist; J Fischer; S Y Kim; S M Stover; T Garcia-Nolen; K Hayashi; J Liu; A S Kapatkin
Journal:  Vet Comp Orthop Traumatol       Date:  2011-09-21       Impact factor: 1.358

6.  The teratoma assay: an in vivo assessment of pluripotency.

Authors:  Robin L Wesselschmidt
Journal:  Methods Mol Biol       Date:  2011

Review 7.  The role of pro- and anti-inflammatory cytokines in the pathogenesis of spontaneous canine CNS diseases.

Authors:  I Spitzbarth; W Baumgärtner; A Beineke
Journal:  Vet Immunol Immunopathol       Date:  2012-04-10       Impact factor: 2.046

8.  Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods.

Authors:  Courtney Paul; Amer F Samdani; Randal R Betz; Itzhak Fischer; Birgit Neuhuber
Journal:  Spine (Phila Pa 1976)       Date:  2009-02-15       Impact factor: 3.468

9.  Human epidermal neural crest stem cells (hEPI-NCSC)--characterization and directed differentiation into osteocytes and melanocytes.

Authors:  Oliver Clewes; Alla Narytnyk; Kevin R Gillinder; Andrew D Loughney; Alison P Murdoch; Maya Sieber-Blum
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

10.  Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny.

Authors:  Michal Gropp; Vitali Shilo; Gilad Vainer; Miri Gov; Yaniv Gil; Hanita Khaner; Limor Matzrafi; Maria Idelson; Juri Kopolovic; Naomi B Zak; Benjamin E Reubinoff
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more
  7 in total

1.  Adaptation of the Basso-Beattie-Bresnahan locomotor rating scale for use in a clinical model of spinal cord injury in dogs.

Authors:  Rachel B Song; D Michele Basso; Ronaldo C da Costa; Lesley C Fisher; Xiaokui Mo; Sarah A Moore
Journal:  J Neurosci Methods       Date:  2016-05-04       Impact factor: 2.390

Review 2.  Targeting Translational Successes through CANSORT-SCI: Using Pet Dogs To Identify Effective Treatments for Spinal Cord Injury.

Authors:  Sarah A Moore; Nicolas Granger; Natasha J Olby; Ingo Spitzbarth; Nick D Jeffery; Andrea Tipold; Yvette S Nout-Lomas; Ronaldo C da Costa; Veronika M Stein; Linda J Noble-Haeusslein; Andrew R Blight; Robert G Grossman; D Michele Basso; Jonathan M Levine
Journal:  J Neurotrauma       Date:  2017-03-22       Impact factor: 5.269

Review 3.  Urological Sequelae to Acute Spinal Cord Injury in Pet Dogs: A Natural Disease Model of Neuropathic Bladder Dysfunction.

Authors:  Laurie Cook; Julie Byron; Sarah Moore
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

4.  Neurotrophin-3 released from implant of tissue-engineered fibroin scaffolds inhibits inflammation, enhances nerve fiber regeneration, and improves motor function in canine spinal cord injury.

Authors:  Ge Li; Ming-Tian Che; Xiang Zeng; Xue-Cheng Qiu; Bo Feng; Bi-Qin Lai; Hui-Yong Shen; Eng-Ang Ling; Yuan-Shan Zeng
Journal:  J Biomed Mater Res A       Date:  2018-04-25       Impact factor: 4.396

5.  Transplantation of encapsulated autologous olfactory ensheathing cell populations expressing chondroitinase for spinal cord injury: A safety and feasibility study in companion dogs.

Authors:  Jon Prager; Joe Fenn; Mark Plested; Leticia Escauriaza; Tracy van der Merwe; Barbora King; Divya Chari; Liang-Fong Wong; Nicolas Granger
Journal:  J Tissue Eng Regen Med       Date:  2022-06-10       Impact factor: 4.323

6.  Human epidermal neural crest stem cells as a source of Schwann cells.

Authors:  Motoharu Sakaue; Maya Sieber-Blum
Journal:  Development       Date:  2015-08-06       Impact factor: 6.868

Review 7.  Emerging and Adjunctive Therapies for Spinal Cord Injury Following Acute Canine Intervertebral Disc Herniation.

Authors:  Melissa J Lewis; Nicolas Granger; Nick D Jeffery
Journal:  Front Vet Sci       Date:  2020-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.